Trevi Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Trevi Therapeutics, Inc. (TRVI) reported Increase (Decrease) in Accrued Liabilities of -$390.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- Trevi Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $685.00K, a 37.55% increase year-over-year.
- Trevi Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.07M.
- Trevi Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$555.00K.
- Trevi Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $143.00K, a 93.50% decline year-over-year.
- Trevi Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$1.42M, a 155.21% decline from fiscal 2024.
- Trevi Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $2.56M, a 4828.85% increase from fiscal 2023.
- Trevi Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $52.00K.
- Trevi Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$639.00K, a 290.18% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $685.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$390.00K 10-Q · filed 2026-08-06 | -$945.00K derived: sum of 3 quarters · filed 2026-08-06 | -$802.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$1.07M 10-Q · filed 2026-05-05 | -$1.63M derived: sum of 2 quarters · filed 2026-05-05 | -$1.49M derived: sum of 3 quarters · filed 2026-05-05 | -$989.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$555.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$412.00K derived: sum of 2 quarters · filed 2026-03-17 | $86.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.42M 10-K · filed 2026-03-17 | ||
| 2025-09-30 | $143.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $641.00K derived: sum of 2 quarters · filed 2026-08-06 | -$860.00K 10-Q · filed 2025-11-13 | -$1.57M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $498.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.00M 10-Q · filed 2026-08-06 | -$1.72M derived: sum of 3 quarters · filed 2026-08-06 | $485.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$1.50M 10-Q · filed 2026-05-05 | -$2.21M derived: sum of 2 quarters · filed 2026-05-05 | -$13.00K derived: sum of 3 quarters · filed 2026-05-05 | $2.00M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | -$713.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.49M derived: sum of 2 quarters · filed 2026-03-17 | $3.50M derived: sum of 3 quarters · filed 2026-03-17 | $2.56M 10-K · filed 2026-03-17 | ||
| 2024-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.22M derived: sum of 2 quarters · filed 2025-11-13 | $3.28M 10-Q · filed 2025-11-13 | $3.30M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.07M 10-Q · filed 2025-08-07 | $1.10M derived: sum of 3 quarters · filed 2025-08-07 | $1.92M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | -$940.00K 10-Q · filed 2025-05-08 | -$916.00K derived: sum of 2 quarters · filed 2025-05-08 | -$93.00K derived: sum of 3 quarters · filed 2025-05-08 | -$825.00K derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $847.00K derived: sum of 2 quarters · filed 2025-03-18 | $115.00K derived: sum of 3 quarters · filed 2025-03-18 | $52.00K 10-K · filed 2025-03-18 | ||
| 2023-09-30 | $823.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $91.00K derived: sum of 2 quarters · filed 2024-11-06 | $28.00K 10-Q · filed 2024-11-06 | -$1.27M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | -$732.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$795.00K 10-Q · filed 2024-08-08 | -$2.09M derived: sum of 3 quarters · filed 2024-08-08 | -$1.78M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | -$63.00K 10-Q · filed 2024-05-07 | -$1.36M derived: sum of 2 quarters · filed 2024-05-07 | -$1.05M derived: sum of 3 quarters · filed 2024-05-07 | -$716.00K derived: sum of 4 quarters · filed 2024-05-07 | ||
| 2022-12-31 | -$1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$989.00K derived: sum of 2 quarters · filed 2024-03-20 | -$653.00K derived: sum of 3 quarters · filed 2024-03-20 | -$639.00K 10-K · filed 2024-03-20 | ||
| 2022-09-30 | $307.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $643.00K derived: sum of 2 quarters · filed 2023-11-09 | $657.00K 10-Q · filed 2023-11-09 | $670.00K 10-Q · filed 2022-11-10 | $1.21M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $336.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $350.00K 10-Q · filed 2023-08-10 | $409.00K 10-Q · filed 2022-08-11 | $906.00K derived: sum of 3 quarters · filed 2023-08-10 | $996.00K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $14.00K 10-Q · filed 2023-05-11 | $570.00K derived: sum of 2 quarters · filed 2023-05-11 | $660.00K derived: sum of 3 quarters · filed 2023-05-11 | -$97.00K derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $556.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $646.00K derived: sum of 2 quarters · filed 2023-03-16 | -$111.00K derived: sum of 3 quarters · filed 2023-03-16 | $336.00K 10-K · filed 2023-03-16 | ||
| 2021-09-30 | $90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$667.00K derived: sum of 2 quarters · filed 2022-11-10 | -$220.00K 10-Q · filed 2022-11-10 | -$1.49M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$757.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$310.00K 10-Q · filed 2022-08-11 | -$1.58M derived: sum of 3 quarters · filed 2022-08-11 | -$182.00K derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $447.00K 10-Q · filed 2022-05-12 | -$822.00K derived: sum of 2 quarters · filed 2022-05-12 | $575.00K derived: sum of 3 quarters · filed 2022-05-12 | -$1.06M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $128.00K derived: sum of 2 quarters · filed 2022-03-17 | -$1.51M derived: sum of 3 quarters · filed 2022-03-17 | -$101.00K 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$239.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.17M 10-Q · filed 2021-11-10 | $222.00K derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | -$1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$229.00K 10-Q · filed 2021-08-12 | -$1.18M derived: sum of 3 quarters · filed 2021-08-12 | -$1.07M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $1.41M 10-Q · filed 2021-05-13 | $461.00K derived: sum of 2 quarters · filed 2021-05-13 | $564.00K derived: sum of 3 quarters · filed 2021-05-13 | $1.94M derived: sum of 4 quarters · filed 2021-05-13 | ||
| 2019-12-31 | -$946.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$843.00K derived: sum of 2 quarters · filed 2021-03-25 | $536.00K derived: sum of 3 quarters · filed 2021-03-25 | $1.42M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $103.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.48M derived: sum of 2 quarters · filed 2020-11-12 | $2.36M 10-Q · filed 2020-11-12 | $3.17M derived: sum of 4 quarters · filed 2020-11-12 | ||
| 2019-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $2.26M 10-Q · filed 2020-08-13 | $3.07M derived: sum of 3 quarters · filed 2020-08-13 | $3.88M derived: sum of 4 quarters · filed 2020-08-13 | ||
| 2019-03-31 | $880.00K 10-Q · filed 2020-05-07 | $1.69M derived: sum of 2 quarters · filed 2020-05-07 | $2.50M derived: sum of 3 quarters · filed 2020-05-07 | $2.45M derived: sum of 4 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $807.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $1.62M derived: sum of 2 quarters · filed 2020-03-16 | $1.57M derived: sum of 3 quarters · filed 2020-03-16 | $772.00K 10-K · filed 2020-03-16 | ||
| 2018-09-30 | $817.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $764.00K derived: sum of 2 quarters · filed 2019-11-14 | -$35.00K 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | -$53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$852.00K 10-Q · filed 2019-08-12 | ||||
| 2018-03-31 | -$799.00K 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |